Treatment of glaucoma using phosphodiesterase inhibitors
Patent 5011843 Issued on April 30, 1991. Estimated Expiration Date: 
June 1, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 1, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorAssigneeApplicationNo. 531729 filed on 06/01/1990US Classes:514/266.3, Chalcogen bonded directly to a ring carbon of the 1,3-diazine ring of the quinazoline ring system514/266.31Carbocyclic ring bonded directly to a ring carbon of the quinazoline ring systemExaminersPrimary: Friedman, Stanley J.Assistant: Fay, Zohreh Attorney, Agent or FirmInternational ClassA61K 031/505AbstractLowering of intraocular pressure, e.g. in the treatment of glaucoma is carried out by administering a phosphodiesterase inhibitor to a patient. Particular ophthalmic pharmaceutical compositions are disclosed for topical application to the eye. | |
